Optimizing mHSPC Treatment: The Evidence for Early Intensification
Watch Professor Fred Saad, Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center, as he describes the evolution of standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) from androgen-deprivation therapy (ADT) alone to combination treatment with novel hormonal therapy (NHT).